BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240710T080000
DTEND;TZID=Europe/Brussels:20240711T170000
DTSTAMP:20260527T003109
CREATED:20240531T135225Z
LAST-MODIFIED:20240531T135227Z
UID:7893-1720598400-1720717200@www.europabio.org
SUMMARY:CURIOUS­ FUTURE INSIGHT™ CONFERENCE
DESCRIPTION:Over the millennia science & technology have steadily advanced\, but key unsolved challenges remain\, and much more is possible. The Curious – Future Insight™ Conference brings together some of the world’s brightest scientists and most accomplished innovators to present their work and explore the future of science and technology\, solving the challenges of today and enabling the dreams of a better tomorrow. \n\n\n\nThe Curious – Future Insight™ conference featurestop speakers and Nobel laureates from all over theworld\, among them: \n\n\n\n\nEmmanuelle Charpentier\, MPI (2018)\n\n\n\nSteven Chu\, Stanford University (2024)\n\n\n\nRobert Langer\, MIT (2024)\n\n\n\nSatya Nadella\, CEO Microsoft (2018)\n\n\n\nUğur Şahin\, CEO BioNTech (2024)\n\n\n\nRandy Schekman\, Berkeley (2024)\n\n\n\nThomas C. Südhof\, Stanford University (2024\, 2022)\n\n\n\nCraig Venter\, Craig Venter Institute (2018)
URL:https://www.europabio.org/event/curious-future-insight-conference/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Curious-Insights-Banner-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240626T170000
DTEND;TZID=Europe/Brussels:20240626T190000
DTSTAMP:20260527T003109
CREATED:20240429T092024Z
LAST-MODIFIED:20240513T092250Z
UID:7743-1719421200-1719428400@www.europabio.org
SUMMARY:NAC Belgian Presidency Summer Reception
DESCRIPTION:EuropaBio\, bio.be/essenscia\, and flanders.bio biotechnology associations are organising a summer reception in Brussels for its members and invited guests to mark the end of the Belgium Council Presidency of the European Union and celebrate what best is made in Belgium – (beyond waffles and beers)\, biotechnology! \n\n\n\nWe will present the outcomes of our National Associations Council Presidency Summit “Made in Belgium for Europe“\, with recommendations on advanced therapies for rare diseases and microorganisms’ role in agricultural applications.  \n\n\n\nIf you wish for more details\, please reach out to communications@europabio.org
URL:https://www.europabio.org/event/nac-belgian-presidency-summer-reception/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-1-NAC-RECEPTION.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240613T113000
DTEND;TZID=Europe/Brussels:20240613T130000
DTSTAMP:20260527T003109
CREATED:20240513T142126Z
LAST-MODIFIED:20240513T142128Z
UID:7789-1718278200-1718283600@www.europabio.org
SUMMARY:Industrial Biotechnology Day (2nd edition) - Biotechnology as key enabling technology for EU Strategies and Ambitions
DESCRIPTION:Explore how industrial biotechnologies can achieve Europe’s environmental ambitions. Discussions will centre on exploring both regulatory frameworks and technological advancements\, identifying our core strengths and opportunities\, and pinpointing areas for improvement. From evaluating feedstocks and industrial capabilities to overcoming regulatory challenges\, join us in shaping a sustainable path forward for the European chemical industry through biotech innovations. \n\n\n\nThis session is organised by Cefic Sector Groups: EFCG\, EFG and Biochem Europe; EuropaBio and SICOS. \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/industrial-biotechnology-day-2nd-edition-biotechnology-as-key-enabling-technology-for-eu-strategies-and-ambitions/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Healthcare-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240516T090000
DTEND;TZID=Europe/Brussels:20240516T180000
DTSTAMP:20260527T003109
CREATED:20240118T152254Z
LAST-MODIFIED:20240118T152720Z
UID:7279-1715850000-1715882400@www.europabio.org
SUMMARY:Knowledge for Growth
DESCRIPTION:Get ready for the touchdown of Europe’s finest life sciences conference\, Knowledge for Growth\, on May 16\, 2024\, in the vibrant city of Antwerp\, Belgium!Elevate your network by rubbing shoulders with decision-makers from biotech\, pharma\, and MedTech\, alongside investors\, universities\, cutting-edge research institutes\, policymakers\, and competence providers. Join over 1000 life sciences trailblazers representing 500+ companies & organizations! Uncover the future with our riveting programme\, delivering key insights into the global and regional life sciences landscape. Engage in dynamic B2B partnering\, explore groundbreaking innovations at the trade fair\, and seize endless networking opportunities.Ready to be part of the life sciences revolution? Secure your spot now here! #KnowledgeForGrowth #KFG2024  \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/knowledge-for-growth-2/
LOCATION:Flanders Meeting & Convention Center Antwerp
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240514T200000
DTEND;TZID=Europe/Brussels:20240515T180000
DTSTAMP:20260527T003109
CREATED:20240311T142703Z
LAST-MODIFIED:20240311T142744Z
UID:7536-1715716800-1715796000@www.europabio.org
SUMMARY:AseBio Investor Day
DESCRIPTION:We are thrilled to announce that AseBio will hold the fifth edition of the AseBio Investor Day at the gorgeous Kursaal conference center in San Sebastián (Spain) on the 15th of May. The AseBio Investor Day is a forum that aims to connect the Spanish biotechnology industry with national and international investors. \n\n\n\nSince its first edition (Barcelona\, 2017)\, the event has attracted national and international investors\, contributing to give visibility to the national biotechnology industry. AseBio Investor Day also fosters networking between investors from Spain and the rest of the world. \n\n\n\nAseBio Investor Day includes a program of round tables where relevant topics on investment and finance will be addressed\, one-to-one meetings and startup pitch presentations. There will also be socials where you can meet your peers and biotech entrepreneurs. \n\n\n\nMeeting Spanish biotechnology is an opportunity to access new deal flow opportunities. Spain is the 9th largest originator of knowledge in biotechnology by number of papers. As of 2023 there were about 900 firms fully dedicated to biotechnology and 270 firms partially dedicated to biotechnology. In 2022 the sector attracted €142 million. \n\n\n\nIn our last edition more than 260 attendees participated in Investor Day and more than 330 one-to-one meetings were held through our matchmaking tool. \n\n\n\nSan Sebastián is a beautiful coastal town in the Spanish Basque Country. The city boasts stunning beaches\, a rich gastronomical tradition with one to the highest densities of Michelin star restaurants in the world\, splendid architecture and a thriving cultural life. The event will take place immediately after BioEquity\, which this year will be held on May 14 and May 15 in the same venue. \n\n\n\nIf you are planning to attend BioEquity why not extend your stay one more day and join us for an opportunity to meet Spanish biotechnology. Investors are cordially invited to participate in the AseBio Investor Day 2024. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/asebio-investor-day/
LOCATION:Kursaal Zurriola Hiribidea\, 1 20002 Donostia\, Guipuzkoa (Spain)
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Healthcare.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240507T140000
DTEND;TZID=Europe/Brussels:20240507T150000
DTSTAMP:20260527T003109
CREATED:20240429T082059Z
LAST-MODIFIED:20240429T084605Z
UID:7736-1715090400-1715094000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit - Report Launch
DESCRIPTION:“Policy pathways for biomanufacturing in Europe” was the theme of the Biomanufacturing Policy Summit 2024. The upcoming report will summarise the Summit’s keynote speeches and panel discussions and translate them into an analysis to Europe’s biomanufacturing strengths\, weaknesses\, opportunities and threats based on specific policies and industrial examples. \n\n\n\nThe report launch will also feature speakers who will respond to the report’s main conclusions and comment on their alignment with current challenges and future goals. \n\n\n\n\nHanna Freienstein\, Policy Officer\, DG GROW – European Commission\n\n\n\n⁠Jérôme Fabiano\, Deputy Director & Corporate Affairs Director\, EIT Health France\n\n\n\n⁠Per Falholt\, Chief Science Officer\, 21st.BIO\n\n\n\n\nThe boost to biotech and biomanufacturing needs a strong knowledge-based approach and the upcoming report aims to contribute to the discussion. Do not miss the opportunity and be up to date about biomanufacturing in Europe.
URL:https://www.europabio.org/event/europabios-biomanufacturing-policy-summit-report-launch/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-600-x-200-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240416T083000
DTEND;TZID=Europe/Brussels:20240416T120000
DTSTAMP:20260527T003109
CREATED:20240326T082922Z
LAST-MODIFIED:20240326T083218Z
UID:7614-1713256200-1713268800@www.europabio.org
SUMMARY:RARE DISEASES FORUM 2024
DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda.
URL:https://www.europabio.org/event/rare-diseases-forum-2024/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240319T143000
DTEND;TZID=Europe/Brussels:20240319T164500
DTSTAMP:20260527T003109
CREATED:20240213T092326Z
LAST-MODIFIED:20240213T093923Z
UID:7402-1710858600-1710866700@www.europabio.org
SUMMARY:Industrial biotech: Is Europe ready to harness its potential?
DESCRIPTION:A Science | Business closed-door roundtable\, organised in partnership with EuropaBio – followed by networking reception \n\n\n\nOnly By Invitation \n\n\n\n \n\n\nBackground Information \nIn recent years industrial biotechnology – also known as “white” biotech – has emerged as a high-value driver of industrial modernisation and the green transition. Through the innovative use of microorganisms and enzymes\, it has transformative potential for manufacturing\, waste use and the creation of sustainable products in sectors as varied as energy\, textiles\, plastics\, paper\, agriculture and water. While some core processes\, such as fermentation technology\, have been commercially deployed for around 50 years\, the speed of scientific progress and solution development are accelerating exponentially. As such\, it appears that the sector as a whole is truly poised to make the leap from “proof of concept” to mainstream application at the European level.  \nThese take on greater importance when one considers other strategic priorities for the EU. First\, it is clear that for Europe to achieve e.g. its 2030 benchmark for net-zero technology manufacturing in the Green Deal Industrial Plan (GDIP)\, it will need to leverage its full innovation capacity across sectors. Second\, as global demand grows for sustainable solutions to climate\, energy\, biodiversity and food system crises\, Europe is ideally positioned to take market leadership in various domains\, given its research excellence and strong industrial base. And third\, the EU’s proposed Strategic Technologies for Europe Platform (STEP) has already identified biotechnologies among its key value chains to ensure future resilience\, autonomy and competitiveness\, while biotechnology has also been recognised as a critical technology for Europe. \nYet a degree of skepticism remains – both in public and policy circles – about the risk/reward ratio of biotechnologies and their wider value to society. One useful counterpoint is to consider the evolution of health-related biotechnology (often called “red” biotech). Having overcome similar resistance and concerns\, “red” biotech is now deployed at scale throughout the life science and pharmaceutical sectors\, and is acknowledged today as a key component in European health innovation. So how can the lessons learned on that journey be absorbed and applied to other sectors?   \n As the EU prepares for its transition to a new Parliament and Commission\, it is therefore an ideal moment to open a multistakeholder dialogue on how policy and regulatory innovations could increase the European added value of “white” biotech and biomanufacturing in the years to come. This also builds on Ursula von der Leyen’s announcement of a new biotech and biomanufacturing initiative in last September’s state-of-the-union address. Among some of the key issues for consideration: \nWhere can industrial biotech and biomanufacturing contribute most effectively to the GDIP and STEP\, and what are the longer-term implications for boosting the global competitiveness of European companies?\nWhat should underpin a future EU roadmap for advancing “white” biotech and biomanufacturing across sectors\, in line with other long-term strategies and objectives?\nWhich other steps are needed at EU and national level to build future capacity\, such as infrastructure and skills?\nIn which ways can public and private finance best support pioneering “white” biotech firms – large and small – in scaling up and maturing their solutions to market-readiness and mass production levels\, as has happened in the health sector?\nBeyond the CBE Joint Undertaking\, to what extent could Horizon Europe\, FP10 and other key instruments – such as the new biotech & biomanufacturing initiative – strengthen Europe’s industrial biotech R&D ecosystem in the next policy cycle?\nOn March 19\, Science|Business\, in cooperation with EuropaBio\, will convene a select group of senior figures and experts from across the industrial biotech spectrum to address these issues in a closed-door\, invitation-only roundtable. Drawing in part on latest research and real-world applications\, the meeting will identify recommendations to harness the full potential of “white” biotech and biomanufacturing\, and to align its further development with the realisation of key EU policy goals.\n \n \n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFor more information\, please contact: denitsa.nikolova@sciencebusiness.ne \n\n\n\n \n\n\n\n \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/industrial-biotech-is-europe-ready-to-harness-its-potential/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240313T130000
DTEND;TZID=Europe/Brussels:20240313T200000
DTSTAMP:20260527T003109
CREATED:20231213T100000Z
LAST-MODIFIED:20240209T113124Z
UID:7082-1710334800-1710360000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe
DESCRIPTION:The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers\, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative\, regulatory and strategic pathways. \n\n\n\n2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative\, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum\, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries. \n\n\n\n \n\n\n\n13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe\, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception \n\n\n\n \n\n\n\nParticipants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative\, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness\, Green Transition and resilience across sectors. \n\n\n\nFor all enquiries\, please contact our Biomanufacturing Platform Coordinator\, Francisco Castro Alves: f.alves@europabio.org
URL:https://www.europabio.org/event/biomanufacturing-policy-summit-2024-policy-pathways-for-biomanufacturing-in-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Event-Banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240307T130000
DTEND;TZID=Europe/Brussels:20240307T143000
DTSTAMP:20260527T003109
CREATED:20240209T095401Z
LAST-MODIFIED:20240306T151454Z
UID:7385-1709816400-1709821800@www.europabio.org
SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240229T090000
DTEND;TZID=Europe/Brussels:20240301T170000
DTSTAMP:20260527T003109
CREATED:20240214T085311Z
LAST-MODIFIED:20240214T100345Z
UID:7415-1709197200-1709312400@www.europabio.org
SUMMARY:International Congress on Rare Diseases and Orphan Drugs 2024
DESCRIPTION:Navigating the Uncharted: Advancements\, Collaborations\, and Hope in Rare Diseases \n\n\n\nSupported by EuropaBio \n\n\n\n \n\n\n\nAbout the event: \n\n\n\nEmbrace the extraordinary journey into the world of rare diseases at our groundbreaking International Congress\, where innovation\, collaboration\, and hope converge! \n\n\n\nThe International Congress on Rare Diseases and Orphan Drugs is organized by Rare Diseases Greece (RDG)\, member of EURORDIS-Rare Diseases Europe and Boussias Events. \n\n\n\nFollowing the success of the previous years and having advanced the policy agenda on both a national and international level\, the Organizing Committee – consisting of Rare Diseases Greece (RDG)\, the 30-member umbrella organization that represents the country’s rare disease community\, brings together all the key initiatives and stakeholders currently shaping the rare disease landscape with the aim to set a course for the future of rare diseases. \n\n\n\nAttendance details: \n\n\n\nThursday\, 29.02.2024 (Hybrid | Technopolis City of Athens Gasholder 1 – Auditorium “Miltiadis Evert”) & Friday\, 01.03.2024 (Digital) \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nFind out more here
URL:https://www.europabio.org/event/international-congress-on-rare-diseases-and-orphan-drugs-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banner-International-Congress-on-Rare-Diseases-Orphan-Drugs-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240221T100000
DTEND;TZID=Europe/Brussels:20240221T120000
DTSTAMP:20260527T003109
CREATED:20231218T141335Z
LAST-MODIFIED:20240206T094606Z
UID:7206-1708509600-1708516800@www.europabio.org
SUMMARY:Made in Belgium for Europe\, National Associations' Council Presidency Summit
DESCRIPTION:Whether it’s microorganisms revolutionising manufacturing or advanced therapies for rare disease patients\, biotechnology is leading the way\, and Belgium is on it.  \n\n\n\nIf you are a researcher\, entrepreneur\, policy wonk\, or simply curious about the future of biotechnology\, join us in our free online conversation.  \n\n\n\nThis conversation will be public and held online on February 21\, 2024\, from 10:00 to 12:00. If you wish to attend our session\, please register. If you have any questions\, insights or suggestions\, do not hesitate to contact José Peres at j.peres@europabio.org. \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nDownload the Agenda
URL:https://www.europabio.org/event/made-in-belgium-for-europe-national-associations-council-presidency-summit/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Banner-Event-Website-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240214T080000
DTEND;TZID=Europe/Brussels:20240214T170000
DTSTAMP:20260527T003109
CREATED:20240130T125205Z
LAST-MODIFIED:20240130T125207Z
UID:7333-1707897600-1707930000@www.europabio.org
SUMMARY:Europe Rare Disease Summit 2024
DESCRIPTION:How to improve and learn about Government Plans\, Access & Financing\, Clinical Research and Innovation\, Artificial Intelligence and Data\, and Social & Patient. \n\n\n\nJoin our very own Healthcare Policy Senior Manager\, Adrien Samson in Madrid where he will be speaking in the panel “Innovation\, Funding and Access to Orphan Drugs: Challenges and Opportunities” between 12:15 and 13:00. \n\n\n\n \n\n\n\nWe are thrilled to announce the eagerly awaited second edition of the Europe Rare Disease Summit\, set to take place in February. Joining forces from all corners of Europe\, this prestigious event brings together leading researchers\, healthcare professionals\, patient advocates\, policymakers\, industry experts\, and rare disease patients and families. \n\n\n\nThe summit emphasizes the power of collaboration and solidarity in facing rare diseases. Together\, we can accelerate research\, enhance patient care\, and improve outcomes\, offering a brighter future for those affected by rare diseases. \n\n\n\nKey Objectives: \n\n\n\nEmpowering Patients: Putting patients at the heart of our efforts\, we strive to enhance their access to quality care and support\, while advocating for their rights and unique challenges. \n\n\n\nAdvancing Research: Renowned scientists will present groundbreaking discoveries\, fostering cross-disciplinary collaboration to propel rare disease research forward. \n\n\n\nBuilding Collaborative Networks: A platform for stakeholders to connect\, exchange ideas\, and form strategic partnerships\, bridging gaps in research\, treatment\, and support. \n\n\n\nInfluencing Policy: By engaging policymakers\, we seek to drive positive changes and better support the rare disease community. \n\n\n\nEngaging Program Highlights: Expect a dynamic lineup of keynote speeches\, interactive workshops\, panel discussions and networking opportunities. Share experiences\, learn from experts\, and inspire change. \n\n\n\nLocation and Dates: Prepare to be inspired in the vibrant setting of Madrid on February 14th. \n\n\n\nWho will Attend: \n\n\n\nRare Disease AdvocatesResearchers and ScientistsHealthcare ProfessionalsIndustry LeadersPolicymakers and Government RepresentativesPharmaceutical and Biotech CompaniesInvestors and Venture CapitalistsAcademics and Students
URL:https://www.europabio.org/event/europe-rare-disease-summit-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banner-ERDS-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260527T003109
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240110T080000
DTEND;TZID=Europe/Brussels:20240125T170000
DTSTAMP:20260527T003109
CREATED:20231213T130812Z
LAST-MODIFIED:20231213T131255Z
UID:7175-1704873600-1706202000@www.europabio.org
SUMMARY:IHI Call Days - Calls 6 & 7
DESCRIPTION:The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium. \n\n\n\nIHI call 7 (single-stage) – info sessions\n\n\n\n10-12 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentWednesday 10 January | 10:30-11:30 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 10 January | 14:30-15:30 \n\n\n\nIHI rules and procedures for single-stage callsThursday 11 January | 10:30-11:30 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 11 January | 14:30-15:30 \n\n\n\nManaging the financial aspects of proposals for single-stage callsFriday 12 January | 10:30-11:30 \n\n\n\nIHI call 6 (two-stage) – info sessions\n\n\n\n15-16 January 2024 \n\n\n\nIHI rules and procedures for two-stage callsMonday 15 January | 14:30-15:30 \n\n\n\nCall 6\, topic 2: Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-makingTuesday 16 January | 10:30-11:30 \n\n\n\nCall 6\, topic 1: Support healthcare system resilience through a focus on persistency in the treatment of chronic diseasesTuesday 16 January | 14:30-15:30 \n\n\n\nIHI call 7 (single-stage) – pitching sessions\n\n\n\n23-25 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentTuesday 23 January | 14:30-16:00 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 24 January | 14:30-16:00 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 25 January | 14:30-16:00
URL:https://www.europabio.org/event/ihi-call-days-calls-6-7/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/news-cover.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231201T083000
DTEND;TZID=Europe/Brussels:20231201T094500
DTSTAMP:20260527T003109
CREATED:20231031T084455Z
LAST-MODIFIED:20231031T084520Z
UID:7041-1701419400-1701423900@www.europabio.org
SUMMARY:EFIB 2023 Rotterdam Statement wider launch
DESCRIPTION:Industrial biotechnology for a sustainable and resilient global Europe  \n\n\n\nAs the EU looks ahead to the European elections in 2024\, with a new EU Commission mandate and Work Programme\, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology. \n\n\n\nBuilding on this momentum\, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership\, resilience and competitiveness. \n\n\n\nWe invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election. \n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/efib-2023-rotterdam-statement-wider-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Vilnius-Statement-Event-600-×-260px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231130T143000
DTEND;TZID=Europe/Brussels:20231130T160000
DTSTAMP:20260527T003109
CREATED:20231018T092656Z
LAST-MODIFIED:20231018T113625Z
UID:7003-1701354600-1701360000@www.europabio.org
SUMMARY:EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs
DESCRIPTION:Hybrid Event | Invitation Only \n\n\n\n\n\nEuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN)\, the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals\, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry. \n\n\n\nOn 1 December 2022\, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN. \n\n\n\nWith the proposals now presented and being negotiated by the European Parliament and the Council\, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs\, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.   \n\n\n\n \n\n\n\nProgramme \n\n\n\nThe 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients\, regulators\, policy-makers\, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions. \n\n\n\n1. Introductions \n\n\n\n2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament \n\n\n\n3. Roundtable topic 1:  How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation? \n\n\n\n4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas? \n\n\n\n5. Conclusions \n\n\n\nIf you would like to attend\, please contact Adrian Lincoln\, a.lincoln@europabio.org
URL:https://www.europabio.org/event/europabio-patient-bioforum-2023-roundtable-on-advancing-solutions-for-unmet-medical-needs/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231106T153000
DTEND;TZID=Europe/Brussels:20231106T163000
DTSTAMP:20260527T003109
CREATED:20231013T105949Z
LAST-MODIFIED:20231013T105951Z
UID:6985-1699284600-1699288200@www.europabio.org
SUMMARY:BIO Europe 2023
DESCRIPTION:The European Pharmaceutical Legislation – Will it keep the light on for biotech in Europe? \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 6th of November in Munich for her panel discussing what the legislation brings\, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version\, that it works for both\, the biotech ecosystem\, maintaining innovation pipelines\, and patients.
URL:https://www.europabio.org/event/bio-europe-2023/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-113155.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231101T080000
DTEND;TZID=Europe/Brussels:20231102T170000
DTSTAMP:20260527T003109
CREATED:20231013T082312Z
LAST-MODIFIED:20231013T082314Z
UID:6977-1698825600-1698944400@www.europabio.org
SUMMARY:World Orphan Drug Congress
DESCRIPTION:The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. \n\n\n\nJoin our Director General\, Dr. Claire Skentelbery on the 1st of November for her Keynote Panel: How to navigate the new legislation to enable orphan drug developers to stay innovative and profitable in Europe. \n\n\n\nAs well as on the 2nd on November for her Panel: How to enable SME’s to obtain greater market access.
URL:https://www.europabio.org/event/world-orphan-drug-congress/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-13-101414.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231024T080000
DTEND;TZID=Europe/Brussels:20231025T170000
DTSTAMP:20260527T003109
CREATED:20230413T124141Z
LAST-MODIFIED:20230525T155522Z
UID:6110-1698134400-1698253200@www.europabio.org
SUMMARY:EFIB 2023 - Industrial biotechnology for a sustainable and resilient global Europe
DESCRIPTION:EuropaBio is pleased to announce that this year’s edition of EFIB\, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Industrial biotechnology for a sustainable and resilient global Europe’\, will take place 24-25 October 2023 in Rotterdam\, The Netherlands. EuropaBio is partnering with local hosts HollandBio and ChemistryNL to bring EFIB 2023 to Rotterdam. \n\n\n\nNow in its 16th year\, EFIB will be dedicated to exploring how industrial biotechnology and the bioeconomy supports European competitiveness. EFIB brings together professionals from across the value chain to discuss advancements from industrial biotechnology and its contribution towards positioning Europe as a global leader in addressing societal and sustainability challenges. Participants include industry of all sizes\, as well as the community that enables industry to deliver\, including researchers\, policy makers\, regulators\, and global organisations. \n\n\n\nOur two-day programme includes inspiring plenaries\, a start-up pitching hour and will explore our four thematic areas – Food\, Feed & Nutrition; Sustainable Biomaterials; Bioprocesses & Technologies; and Sustainable Finance – as well as new frontiers like biomanufacturing. The programme is complemented by the exhibition: including start-ups and SMEs in our SME Village\, the academic poster presentation in our Innovation Campus\, and exhibitors from industry and national associations. Interested in exhibiting? Check out our sponsorship page.   \n\n\n\nAttending EFIB 2023 will allow you to learn about the latest market trends and research findings in industrial biotechnology and network with key stakeholders.  \n\n\n\n\nRegister Here\n\n\n\n\nFor more information visit our website and subscribe to our newsletter.
URL:https://www.europabio.org/event/efib-2023-industrial-biotechnology-for-a-sustainable-and-resilient-global-europe/
CATEGORIES:EFIB
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/Copy-of-General-template-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231023T124000
DTEND;TZID=Europe/Brussels:20231023T141000
DTSTAMP:20260527T003109
CREATED:20231012T114428Z
LAST-MODIFIED:20231012T115640Z
UID:6973-1698064800-1698070200@www.europabio.org
SUMMARY:TOPRA Symposium 2023: advancing global healthcare together
DESCRIPTION:Session: Update on EU new regulatory legislation and a view from different angles \n\n\n\nJoin our very own Valentin Plouchard who will be speaking at the TOPRA Annual Symposium in Lisbon on the 23rd of October.
URL:https://www.europabio.org/event/topra-symposium-2023-advancing-global-healthcare-together/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Screenshot-2023-10-12-133359.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231011T133000
DTEND;TZID=Europe/Brussels:20231011T150000
DTSTAMP:20260527T003109
CREATED:20230920T110911Z
LAST-MODIFIED:20230920T110912Z
UID:6861-1697031000-1697036400@www.europabio.org
SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe.
URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/
CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230929T100000
DTEND;TZID=Europe/Brussels:20230930T190000
DTSTAMP:20260527T003109
CREATED:20230320T153927Z
LAST-MODIFIED:20230320T160626Z
UID:6049-1695981600-1696100400@www.europabio.org
SUMMARY:International Forum on Industrial Biotechnology and Bioeconomy (IFIB)
DESCRIPTION:NETWORKING AND PARTNERSHIPS IN BIOECONOMY AREA \n\n\n\nIFIB – International Forum on Industrial Biotechnology and Bioeconomy aims at strengthening the bioeconomy network in the Euro-Mediterranean area and to promote partnerships. The focus of the Forum is biotechnology\, as provider of new resources for industries. \n\n\n\nIt is organized into round-tables and sessions devoted to specific sub-sectors of industrial biotechnology: bio-based industries\, agro-food\, energy\, environment policies on industrial biotech and bioeconomy\, involving international speakers coming from key sector’s players. \n\n\n\nEdition 2023 > 29/30 September Bari \n\n\n\n\nMore information
URL:https://www.europabio.org/event/international-forum-on-industrial-biotechnology-and-bioeconomy-ifib/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230926T100000
DTEND;TZID=Europe/Brussels:20230928T190000
DTSTAMP:20260527T003109
CREATED:20230320T145053Z
LAST-MODIFIED:20230320T145327Z
UID:6038-1695722400-1695927600@www.europabio.org
SUMMARY:BIOSPAIN 2023
DESCRIPTION:BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain. \n\n\n\nThis year\, BIOSPAIN goes back to Barcelona\, the main biotech cluster in Spain and one of the most dynamic cities in the world. \n\n\n\nThe event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center\, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park\, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/biospain-2023/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230925T120000
DTEND;TZID=Europe/Brussels:20230925T131500
DTSTAMP:20260527T003109
CREATED:20230710T072650Z
LAST-MODIFIED:20230925T072852Z
UID:6450-1695643200-1695647700@www.europabio.org
SUMMARY:The economic power of biotechnology for Europe
DESCRIPTION:The world is at a key point of industrial and societal transition\, driven by advancing technology and the need for competitive\, resilient and sustainable economies. \n\n\n\nBiotechnology is at the heart of this transition across all sectors and it is playing a significant role in shaping Europe’s future. \n\n\n\nEuropean Biotech Week kick starts with a look at how biotechnology performs in the European Union’s economy. \n\n\n\nProfessor Dennis Ostwald\, founder and CEO of the WifOR Institute presents the 2023 edition of EuropaBio’s ‘Measuring the economic footprint of the biotechnology industry in Europe’. Professor Ostwald showcases how biotechnology contributes across healthcare and industrial sectors in the light of Europe’s response to Covid\, global supply chains stressed further by the Russian invasion of Ukraine\, and at a time when Europe also has ambitious climate change goals. \n\n\n\nSpeakers: \n\n\n\nProfessor Dr. Dennis A. Ostwald. Through his studies\, Prof. Ostwald aims to make the importance of health innovations visible and enable evidence-based decision making for a healthy society. He conducts research on topics such as health economics\, the value of impacts\, and international social policy. Prof. Ostwald studied Industrial Engineering and Management at the Technical University of Darmstadt\, Germany and received his PhD from the Chair of Finance and Economic Policy\, Prof. Dr. Dr. h.c. Bert Rürup\, on the topic “Growth and employment effects of the healthcare industry”. As Professor of Economic Research and International Management at the Steinbeis School of International Business and Entrepreneurship (SIBE)\, he wants to develop young talents into responsible managers who understand the interplay between social\, environmental and economic sustainability.  \n\n\n\n \n\n\n\nJoin EuropaBio to understand how biotechnology is increasing its role with Europe’s economy and discuss with Members what this means for sectors\, countries and citizens. \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/the-economic-power-of-biotechnology-for-europe/
CATEGORIES:Biotech Week
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/07/GENERAL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230920T080000
DTEND;TZID=Europe/Brussels:20230921T170000
DTSTAMP:20260527T003109
CREATED:20230615T070358Z
LAST-MODIFIED:20230615T070523Z
UID:6387-1695196800-1695315600@www.europabio.org
SUMMARY:Life Sciences Baltics as a contributor to Lithuania’s innovation ecosystem
DESCRIPTION:Life sciences in Lithuania have been a priority for the government for over a decade. Accelerating faster than almost anywhere else in Europe\, the sector aims to contribute 5% to Lithuania’s GDP by 2030. The close cooperation between actors of the ecosystem is one of the reason for success.   \n\n\n\nCreative collaboration takes place in Lithuania’s innovation ecosystem in a variety of ways\, including events\, cross-promotion\, and sharing of resources. The leading life sciences Baltics event in the region – Life Sciences Baltics – is one of the best examples of these collaborations. \n\n\n\nSince its initiation in 2012\, the forum has aimed to create as many opportunities as it is possible for deeper cooperation between the growing life sciences ecosystems in the Baltics and international partners. \n\n\n\nHeld every two years\, the forum has grown from a 300-person assembly to a community of up to 800 key participants from around 40 countries: corporate CEOs\, startup founders\, tech scouts\, investors\, researchers. It is the largest life sciences event in the Eastern and Central Europe. \n\n\n\nThe event will take place in the Lithuania’s capital city of Vilnius on September 20-21. The pre-registration is already open for participants and exhibitors. \n\n\n\nWhether there is a need to kick off the project\, generate leads\, or engage in valuable partnerships\, Life Sciences Baltics offers a diverse range of interactions for its participants: international conference\, exhibition\, networking spaces\, pitch challenge for startups. \n\n\n\nIt also hosts business delegations and offers an opportunity for side visits to Lithuania’s organizations and institutions. \n\n\n\nThe program of the international conference is divided into sessions with the most trending topics worldwide that are also breakthrough areas in the Baltic countries: gene editing\, CRISPR diagnostics\, AI and digital health innovations\, nanomedicine\, microbiome\, reinvention of clinical trials\, digital biomarkers and many more. \n\n\n\nMany big names have attended Life Sciences Baltics\, among them Thermo Fisher Baltics\, Johnson&Johnson\, Clarivate\, Novartis\, Abbvie\, AstraZeneca\, and others. Nobel prize winners Richard Henderson\, Brian Kobilka\, Dan Shechtman\, CRISPR pioneer Prof. Dr Virginijus Šikšnys were among top conference speakers. \n\n\n\nThe event will keep tabs on the fastest growing startups in the region\, but only 10 hand-picked startups will have an opportunity to showcase who they are in front of a panel of investors. \n\n\n\nThe event is organized by Innovation Agency Lithuania\, an official public agency responsible for the Lithuanian innovation ecosystem and is supported by Lithuania’s local ecosystem actors – Lithuanian biotechnology association\, universities\, hospitals\, business angels and Lithuania’s life sciences enthusiasts.  \n\n\n\nThe Baltics\, and Lithuania in particular\, – the next big thing in life sciences  \n\n\n\nLife Sciences Baltics make it possible to assess the attractiveness of the Baltic countries in close-up – Estonia\, Latvia and Lithuania show their distinct\, but strong potential in the sector. \n\n\n\nThree Baltic countries are particularly seeing a growth in life sciences startups. While average funding per startup is decreasing globally\, it’s increasing in the region.  Lithuania attracts growing VC interest into global solutions produced by local entrepreneurs and scientists. \n\n\n\nFocused on nurturing the next generation of talents\, the local life sciences enterprises in the Baltics excel at creativity and entrepreneurship. In 2021 alone\, Lithuania’s life sciences sector grew by almost 87% and generated revenues of 2 billion euros. \n\n\n\n90% of the output of Lithuania’s life sciences are exported to more than 100 countries worldwide. Lithuanian-made medical and pharmaceutical equipment and other products are trusted by customers in the USA\, Germany\, France\, and elsewhere. \n\n\n\nOne of the most prominent players in Lithuania is Thermo Fisher Scientific Baltics\, which has stimulated the development of Lithuania’s industry during the last decade. This company\, along with other international players in the market\, work with local actors for various R&D projects and supply chain. \n\n\n\n\nFor more details
URL:https://www.europabio.org/event/life-sciences-baltics-as-a-contributor-to-lithuanias-innovation-ecosystem/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230704T100000
DTEND;TZID=Europe/Brussels:20230704T170000
DTSTAMP:20260527T003109
CREATED:20230614T151559Z
LAST-MODIFIED:20230614T151749Z
UID:6377-1688464800-1688490000@www.europabio.org
SUMMARY:Industrial Biotechnologies Day
DESCRIPTION:CEFIC Specialty Chemicals sector groups EFCG\, Biochem Europe and EFG\, together with SICOS\, the French industry association for Fine Chemicals and Biotech\, will jointly hold their first in-person Industrial Biotechnologies Day on July 4th\, 2023 in Brussels. \n\n\n\nSpecialists from the industry\, EU policy makers\, and civil society will come together across four panels to dive into topics such as: \n\n\n\n\nEuropean policies shaping the biotech landscape – what is needed to unleash its full potential?\n\n\n\nEuropean regulatory frameworks – an obstacle to innovation?\n\n\n\nFeedstocks and industrial capacities – what is the role of energy costs?\n\n\n\nNew technologies and future breakthroughs – what to expect and what’s at stake?\n\n\n\n\nConfirmed Speakers: \n\n\n\n\nHans Ingels\, European Commission – Directorate-General for Internal Market\, Industry\, Entrepreneurship and SMEs\n\n\n\nLudo Diels\, Flemish Institute for Technological Research (VITO)\n\n\n\nVincent Touraille\, Sicos\n\n\n\nKarel De Winter\, Bio Base Europe Pilot Plant\n\n\n\nMarcello Buson\, Olon SpA\n\n\n\nFrédéric Van Gansberghe\, Futerro\n\n\n\nClaire Skentelberry\, Europabio\n\n\n\nChristian Le Roux\, Group M21\n\n\n\nHarald Ruissenaars\, Corbion\n\n\n\nEric Bierny\, Galactic\n\n\n\nNicolas Martin\, Metex\n\n\n\nThomas Canova\, Solvay\n\n\n\nJulien Honoré\, Roquette\n\n\n\nJuliette Martin\, Seqens\n\n\n\nGwenaël Servant\, Abolis\n\n\n\n\n\nMore details
URL:https://www.europabio.org/event/industrial-biotechnologies-day/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230630T124500
DTEND;TZID=Europe/Brussels:20230630T124500
DTSTAMP:20260527T003109
CREATED:20230321T210403Z
LAST-MODIFIED:20230321T210405Z
UID:6074-1688129100-1688129100@www.europabio.org
SUMMARY:DUTCH BIOTECH EVENT 2023
DESCRIPTION:Join us to celebrate the power of biotech at the Dutch Biotech Event 2023! \n\n\n\nAbout HollandBIO’s Dutch Biotech Event \n\n\n\nThe program features inspiring talks by keynote speakers on biotech and entrepreneurship\, followed by workshops and break-out sessions that contribute to your personal development and that of your company. In addition\, there will be plenty of opportunities for networking during the break\, drinks and vegetarian BBQ. \n\n\n\nWho can join Dutch Biotech Event? \n\n\n\nThe Dutch Biotech Event welcomes HollandBIO members (registration free of charge) and employees of other biotech R&D companies (registration fee €295\,- p.p.)\, with a maximum of 2 delegates per organization. \n\n\n\nWe invite non-member startups to consider a HollandBIO membership (€562\,-/year)\, which besides access to the network & events\, offers many more advantages. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/dutch-biotech-event-2023/
LOCATION:Inn Style\, Herenweg 55\, Maarssen\, 3602 AN\, Netherlands
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230627T180000
DTEND;TZID=Europe/Brussels:20230627T200000
DTSTAMP:20260527T003110
CREATED:20230524T142640Z
LAST-MODIFIED:20230616T172415Z
UID:6330-1687888800-1687896000@www.europabio.org
SUMMARY:NAC Spanish Presidency Summer Reception
DESCRIPTION:EuropaBio\, and AseBio\, the Spanish Association of Biotechnology Companies\, with the support of Merck\, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.  \n\n\n\nThe event will take place on June 27th in Brussels at Comet Meetings – Louise\, from 18-20h. If you wish for more details\, please get in touch with José Peres at j.peres@europabio.org 
URL:https://www.europabio.org/event/nac-spanish-presidency-summer-reception/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/NAC-Summer-Reception-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230627T140000
DTEND;TZID=Europe/Brussels:20230627T160000
DTSTAMP:20260527T003110
CREATED:20230516T093527Z
LAST-MODIFIED:20230517T184028Z
UID:6244-1687874400-1687881600@www.europabio.org
SUMMARY:Reflection seminar and closing party around the EU presidency
DESCRIPTION:On June 27\, a Life Science conference is arranged for EU parliamentarians during Sweden’s EU presidency. \n\n\n\nDirectly after the official conference\, The Royal Academy of Engineering Sciences (IVA) and SwedenBIO invites the public to a seminar with the spotlight on how the suggested EU legislations may affect the life science industry. With examples from the Swedish life science arena\, we show the importance of intellectual property and data protection in the journey from academic research to products and therapies for patients. \n\n\n\nAfterward\, a networking reception is organized by the united life science industry organisations. With drinks\, snacks\, and key speakers\, we ensure that the end of the presidency marks the start of an even stronger united life science industry in Sweden and beyond. \n\n\n\n\nMore details
URL:https://www.europabio.org/event/reflection-seminar-and-closing-party-around-the-eu-presidency/
LOCATION:IVA Conference Center\, Grev Turegatan 15\, Stockholm\, Sweden
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners.jpg
END:VEVENT
END:VCALENDAR